Secondary analysis at 3 years of a phase 3 trial in 263 patients with recurrent or metastatic NPC: tislelizumab plus chemotherapy vs placebo plus chemotherapy improved median PFS (9.6 vs 7.4 months; HR 0.53); OS HR 0.73 (95% CI 0.51-1.05).
Secondary analysisn = 263
Yang et al. First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial